{"query":"Encoded Therapeutics Kartik Ramamoorthi CNS gene therapy news","follow_up_questions":null,"answer":null,"images":[],"results":[{"url":"https://encoded.com/press-releases/encoded-therapeutics-announces-regenerative-medicine-advanced-therapy-rmat-designation-granted-by-u-s-fda-for-etx101-in-scn1a-dravet-syndrome/","title":"News & Events - Encoded Therapeutics","content":"“The FDA's decision to grant RMAT designation highlights the promising clinical efficacy and safety profile we have observed to date,” said Kartik Ramamoorthi,","score":0.99997973,"raw_content":null},{"url":"https://encoded.com/press-releases/asgct2023/","title":"News & Events - Encoded Therapeutics","content":"“Off-target expression in the DRG and other organs has created limitations on gene therapy efficacy optimization,” said Encoded CEO Kartik","score":0.9999461,"raw_content":null},{"url":"https://encoded.com/press-releases/encoded-therapeutics-announces-us-ind-clearance-and-australian-cta-approval-for-dravet-syndrome-gene-therapy-candidate-etx101/","title":"Encoded Therapeutics Announces US IND Clearance and ...","content":"Encoded Therapeutics Announces US IND Clearance and Australian CTA Approval for Dravet Syndrome Gene Therapy Candidate ETX101. Initial studies","score":0.99944717,"raw_content":null},{"url":"https://encoded.com/press-releases/encoded-therapeutics-highlights-progress-in-dravet-syndrome-program-and-pipeline-ahead-of-company-presentation-at-44th-annual-j-p-morgan-healthcare-conference/","title":"News & Events - Encoded Therapeutics","content":"Positive interim efficacy data in 2025 underscore potential of ETX101 as a one-time, disease-modifying medicine for Dravet syndrome –.","score":0.9992267,"raw_content":null},{"url":"https://encoded.com/press-releases/asgct-2022-data-release/","title":"News & Events - Encoded Therapeutics","content":"Encoded Therapeutics Presents Nonclinical Data Showing Genomic Medicine Platform Yields Selective Expression to Optimize Gene Therapy","score":0.99910307,"raw_content":null}],"response_time":1.36,"request_id":"650fb0f2-ef8b-4be1-95d8-0a57e5d8003a"}